Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Clinical and Experimental Nephrology|November 26, 2024
Association of renal volumetry and histological features with marginal donors: risks for donors and recipients in living donor kidney transplantationShunta Hori, Mitsuru Tomizawa, Kuniaki Inoue, et al.
In Vivo (Athens, Greece)|June 27, 2024
Follow-up After Donor Nephrectomy in Living Kidney Donors: How to Manage Living Kidney Donors PostoperativelyShunta Hori, Mitsuru Tomizawa, Kuniaki Inoue, et al.
Clinical and Experimental Nephrology|June 2, 2025
Internal iliac artery calcification score predicts cardiovascular disease and mortality following living-donor kidney transplantationMitsuru Tomizawa, Shunta Hori, Kuniaki Inoue, et al.
Clinical and Experimental Nephrology|February 18, 2026
Vulnerability and short clinical outcomes in patients on the deceased-donor kidney transplant waiting listShunta Hori, Mitsuru Tomizawa, Kuniaki Inoue, et al.
Clinical and Experimental Nephrology|November 23, 2023
Impact of nutrition and inflammation indicators on peritoneal dialysis initiation and managementShunta Hori, Mitsuru Tomizawa, Kuniaki Inoue, et al.
Journal of Vascular Surgery|August 2, 2025
Risk factors for early arteriovenous fistula failure in patients undergoing hemodialysis and comparison of diagnostic prediction modelsShunta Hori, Mitsuru Tomizawa, Kuniaki Inoue, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|October 28, 2022
Clinical significance of limited and extended pelvic lymph node dissection during robot-assisted radical prostatectomy for patients with localized prostate cancer: A retrospective, propensity score matching analysisShunta Hori, Yasushi Nakai, Akira Tachibana, et al.
Diagnostics (Basel, Switzerland)|July 29, 2025
Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Post-Transurethral Resection of Bladder Tumor Infection and PrognosisNobutaka Nishimura, Makito Miyake, Tatsuki Miyamoto, et al.
Bladder Cancer (Amsterdam, Netherlands)|March 24, 2025
Platinum-based chemotherapy rechallenge or enfortumab vedotin after maintenance avelumab or pembrolizumab for locally advanced or metastatic urothelial carcinomaNobutaka Nishimura, Makito Miyake, Norimi Takamatsu, et al.
Pageof 4